New Target Genes for the Peroxisome Proliferator-Activated Receptor- PPAR Antitumour Activity: Perspectives from the Insulin ReceptorReport as inadecuate




New Target Genes for the Peroxisome Proliferator-Activated Receptor- PPAR Antitumour Activity: Perspectives from the Insulin Receptor - Download this document for free, or read online. Document in PDF available to download.

PPAR ResearchVolume 2009 2009, Article ID 571365, 8 pages

Review Article

Department of Clinical and Experimental Medicine “G. Salvatore”, University of Catanzaro “Magna Græcia”, V.le Europa Loc. Germaneto, 88100 Catanzaro, Italy

Chair of Clinical Pathology, University of Catanzaro “Magna Græcia”, V.le Europa Loc. Germaneto, 88100 Catanzaro, Italy

Chair of Endocrinology, University of Catanzaro “Magna Græcia”, V.le Europa Loc. Germaneto, 88100 Catanzaro, Italy

Received 12 January 2009; Accepted 6 May 2009

Academic Editor: Jihan Youssef

Copyright © 2009 Daniela P. Foti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The insulin receptor IR plays a crucial role in mediating the metabolic and proliferative functions triggered by the peptide hormone insulin. There is considerable evidence that abnormalities in both IR expression and function may account for malignant transformation and tumour progression in some human neoplasias, including breast cancer. PPAR is a ligand-activated, nuclear hormone receptor implicated in many pleiotropic biological functions related to cell survival and proliferation. In the last decade, PPAR agonists—besides their known action and clinical use as insulin sensitizers—have proved to display a wide range of antineoplastic effects in cells and tissues expressing PPAR , leading to intensive preclinical research in oncology. PPAR and activators affect tumours by different mechanisms, involving cell proliferation and differentiation, apoptosis, antiinflammatory, and antiangiogenic effects. We recently provided evidence that PPAR and agonists inhibit IR by non canonical, DNA-independent mechanisms affecting IR gene transcription. We conclude that IR may be considered a new PPAR “target” gene, supporting a potential use of PPAR agonists as antiproliferative agents in selected neoplastic tissues that overexpress the IR.





Author: Daniela P. Foti, Francesco Paonessa, Eusebio Chiefari, and Antonio Brunetti

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents